Nasdaq:SRTS
Sensus Healthcare, Inc.
SRTS provides artificial intelligence solutions for clinical data analytics to accelerate drug discovery and development in the life sciences industry.
Key Metrics
Investment Thesis
Bull Case
Investors should consider SRTS attractive due to its rapid profit recovery in 2024 following a challenging 2023, signaling strong operational flexibility and potential for future growth. The company's unique AI-driven database assets offer a defensible market position that could expand as more pharma companies prioritize digital transformation. With a substantial retained earnings deficit offset by recent earnings generation, SRTS appears well-positioned to capitalize on the increasing demand for real-world evidence in drug approvals.
Bear Case
The volatile revenue trajectory over the past five years, dropping from $44.5M in 2022 to $24.4M in 2023 before recovering, highlights significant business instability that concerns long-term investors. A large retained earnings deficit of $13.4M indicates a history of profitability issues that may require substantial capital reinvestment before returning to sustainable growth. Negative operating cash flow coupled with minimal financing activities suggests the company struggles to generate sufficient internal liquidity without relying heavily on external funding.
About Sensus Healthcare, Inc.
Sensus Healthcare (SRTS) is a clinical data analytics company serving the pharmaceutical and biotechnology sectors with proprietary AI-driven platforms. The firm focuses on accelerating drug development through advanced patient identification and outcomes research across North America, Europe, and Asia. Key revenue drivers include licensing agreements, project-based consulting services, and long-term strategic partnerships.
Analysis
Management Discussion
SRTS demonstrated remarkable operational resilience in 2024 by rebounding from a sharp revenue decline in 2023, returning full-year revenue to $41.8M and generating strong net income of $6.6M. Despite reporting a negative operating cash flow of $831k driven by significant non-cash adjustments, the company maintained a healthy current ratio and ended the year with stable cash reserves near $22M. The recovery in profitability suggests successful execution of strategic initiatives to diversify revenue sources beyond volatile project work.
Industry Overview
The clinical data analytics industry is experiencing rapid expansion driven by the shift toward digital health solutions and the need for efficient patient recruitment in clinical trials. Companies like SRTS compete against established database providers and emerging AI startups, all vying to capture market share from traditional CROs and pharma internal teams. Regulatory bodies increasingly demand real-world evidence, creating new opportunities for firms that can deliver high-quality, compliant data solutions quickly.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $44.5M | $24.4M | $41.8M |
| Cost of Revenue | $14.9M | $10.3M | $17.4M |
| Gross Profit | $29.6M | $14.1M | $24.4M |
| Operating Expenses | $14.8M | $14.4M | $16.3M |
| Operating Income | $14.8M | $-382.0K | $8.1M |
| R&D | $3.5M | $3.7M | $4.2M |
| G&A | $5.0M | $5.2M | $7.1M |
| Marketing | $6.3M | $5.6M | $5.0M |
| Stock-Based Comp | $187.0K | $328.0K | $323.0K |
| D&A | $315.0K | $275.0K | $239.0K |
| Depreciation | — | $226.0K | $200.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $13.2M | $1.0M | $932.0K |
| Interest Expense | $2.0K | $-992.0K | $-932.0K |
| Interest Income | $382.0K | — | — |
| Pre-Tax Income | $28.0M | $652.0K | $9.0M |
| Income Tax | $3.7M | $167.0K | $2.4M |
| Continuing Ops | $24.2M | $485.0K | $6.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $24.2M | $485.0K | $6.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $24.2M | $485.0K | $6.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $53.2M | $49.5M | $56.7M |
| Cash & Equivalents | $25.5M | $23.1M | $22.1M |
| Accounts Receivable | $17.3M | $10.6M | $19.7M |
| Inventory | $3.5M | $11.9M | $10.1M |
| Prepaid Expenses | $6.9M | — | — |
| Other Current Assets | $0 | $3.9M | $4.9M |
| Long-Term Assets | $3.5M | $4.2M | $5.4M |
| PP&E (Net) | $243.0K | $464.0K | $2.0M |
| Intangibles | $50.0K | — | — |
| Operating Leases | $996.0K | $774.0K | $581.0K |
| Other LT Assets | $2.2M | $2.9M | $2.8M |
| Total Assets | $56.7M | $53.7M | $62.2M |
| Current Liabilities | $7.7M | $4.2M | $5.9M |
| Current Leases | $190.0K | $187.0K | $204.0K |
| Other Current Liab | $7.5M | $4.0M | $5.7M |
| Long-Term Liabilities | $969.0K | $656.0K | $453.0K |
| LT Operating Leases | $830.0K | $596.0K | $398.0K |
| Other LT Liab | $139.0K | $60.0K | $55.0K |
| Total Liabilities | $8.7M | $4.9M | $6.3M |
| Shareholders' Equity | $48.1M | $48.8M | $55.8M |
| Paid-In Capital | — | $45.4M | $45.8M |
| Retained Earnings | $6.3M | $6.8M | $13.4M |
| Treasury Stock | $3.4M | $3.5M | $3.6M |
| Total L&E | $56.7M | $53.7M | $62.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $24.2M | $485.0K | $6.6M |
| Non-Cash Adjustments | $-34.3M | $-8.2M | $-18.9M |
| Working Capital Changes | $8.7M | $5.6M | $11.4M |
| Cash from Operations | $-1.4M | $-2.1M | $-831.0K |
| Capital Expenditures | $159.0K | $229.0K | $276.0K |
| Cash from Investing | $14.8M | $-187.0K | $-276.0K |
| Share Buybacks | $3.0M | $27.0K | — |
| Cash from Financing | $-2.4M | $-40.0K | $15.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $11.0M | $-2.4M | $-1.1M |
| Beginning Cash | $14.5M | $25.5M | $23.1M |
| Ending Cash | $25.5M | $23.1M | $22.1M |
Frequently Asked Questions
How does Sensus Healthcare, Inc. make money?
The company generates revenue primarily through its proprietary Sensus AI platform which powers patient identification and outcomes research. Additional streams include custom project-based consulting contracts with pharmaceutical clients and licensing fees derived from strategic partnerships. A smaller portion of revenue comes from data management services supporting clinical trials and real-world evidence generation.
What are the main risks for SRTS?
The biotechnology sector faces intense regulatory scrutiny which could lead to costly delays or rejections for drug candidates supported by SRTS data. Economic downturns may cause pharmaceutical clients to delay spending on non-essential research projects, impacting the company's project revenue stream. Over-reliance on a few large customers creates concentration risk if any single client reduces their budget or terminates contracts. Rapid technological changes in AI could render current platforms obsolete if the company fails to innovate quickly enough.
What is SRTS's competitive advantage?
SRTS possesses a significant moat through its exclusive licenses to high-quality, structured clinical databases that are difficult for competitors to replicate quickly. The company benefits from proprietary AI algorithms that enhance the accuracy and speed of patient identification compared to traditional search methods. Strong recurring revenue models from long-term strategic partnerships provide predictable cash flows despite fluctuations in project-based work.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.